<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00125606</url>
  </required_header>
  <id_info>
    <org_study_id>AML_CR2_allo_HSCT</org_study_id>
    <nct_id>NCT00125606</nct_id>
  </id_info>
  <brief_title>Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide</brief_title>
  <official_title>Randomized Phase 3 Trial for Patients With AML in CR2 Comparing Total Body Irradiation (TBI) With 8Gy/Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deutsche Klinik fuer Diagnostik</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients with acute myeloid leukemia (AML), allogeneic hematopoetic stem cell
      transplantation (HSCT) is one of the most potent treatment options currently available. In
      order to overcome the high risk of fatal treatment-related complications, reduced intensity
      and nonmyeloablative conditioning regimens for allogeneic HSCT are currently being explored
      in various hematological malignancies including AML. At least for allogeneic HSCT in AML, the
      optimal dose-intensity of preparative regimens for disease control at an acceptable rate of
      treatment-related lethal complications has not been determined. The investigators, therefore,
      evaluated reduced intensity myeloablative conditioning with 8 Gy TBI and fludarabine in AML
      patients considered ineligible for conventional conditioning in a phase 2 trial (data
      published in BLOOD by Stelljes et al., 2005). The results suggest that with 8 Gy
      TBI/fludarabine, conditioning related and unrelated donor transplants can be performed in AML
      patients in first or second complete remission (CR) with a remarkably low 2-year non relapse
      mortality (NRM) and satisfactory disease control. Based on these data a randomized phase 3
      trial for patients with AML in CR≥2 is currently being conducted by the Cooperative German
      Transplant Study Group comparing TBI 8 Gy/fludarabine to conventionally dosed conditioning
      with TBI 12 Gy/cyclophosphamide.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    insufficient patient recruitement
  </why_stopped>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>treatment related mortality</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>event free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of acute and chronic graft-versus-host disease (GvHD)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>activity index (ECOG)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>organ function</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>conditioning therapy with 12 Gy TBI / cyclophosphamide 120</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>conditioning therapy with 8 Gy TBI / fludarabine 120</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conditioning for allogeneic HSCT</intervention_name>
    <arm_group_label>conditioning therapy with 12 Gy TBI / cyclophosphamide 120</arm_group_label>
    <arm_group_label>conditioning therapy with 8 Gy TBI / fludarabine 120</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with AML in second complete remission

          -  HLA-identical related (HLA * A, B, and DR) or HLA-compatible unrelated donor with
             maximum of one Ag mismatch

          -  Ages 18-60 years

          -  Written informed consent from the patient

          -  Written informed consent from the donor

          -  No major organ dysfunction

        Exclusion Criteria:

          -  Cardiac failure (New York Heart Association [NYHA] grade II-IV)

          -  Renal failure (creatinine &gt; 2.0 mg/dl)

          -  Hepatic failure (total bilirubin &gt; 3 mg/dl)

          -  Severe neurological/psychiatric disorder

          -  Previous allogeneic HSCT

          -  Contra-indications for used drugs

          -  HIV infection

          -  Non-compliance to processing of personal data according to the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Stelljes, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine/Hematology and Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine/Hematology and Oncology</name>
      <address>
        <city>Muenster</city>
        <state>NRW</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2005</study_first_submitted>
  <study_first_submitted_qc>July 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2005</study_first_posted>
  <last_update_submitted>December 17, 2012</last_update_submitted>
  <last_update_submitted_qc>December 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>allogeneic HSCT</keyword>
  <keyword>reduced intensity conditioning</keyword>
  <keyword>randomized trail</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

